SCHEMBL5779231

SCHEMBL5779231

CC(F)(F)c1cc(Br)ccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.40
HSD11B1 P28845 2/20 0.38
ALDH1A1 P00352 1/20 0.38
KDM1A O60341 2/20 0.36
RXRA P19793 3/20 0.33
GRIN1 Q05586 3/20 0.33
GRIN2B Q13224 3/20 0.33
NOTUM Q6P988 1/20 0.33
RAPGEF4 Q8WZA2 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
IDO1 P14902 1/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
HTR3A P46098 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33
KDR P35968 1/20 0.33
KCNH2 Q12809 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31342658 1.00 NT5E (0.40) NT5EHSD11B1ALDH1A1KDM1ARXRA
SCHEMBL2043993 0.84 NT5E (0.38) NT5EHSD11B1ALDH1A1KDM1ANOTUM
SCHEMBL29268112 0.83 HSD11B1 (0.41) NT5EHSD11B1ALDH1A1KDM1ANOTUM
SCHEMBL264729 0.83 IDO1 (0.47) NT5EKDM1ANOTUMRAPGEF4IDO1
SCHEMBL12791524 0.83 PTGDR2 (0.42) NT5EHSD11B1ALDH1A1PTGDR2KCNH2
SCHEMBL29707579 0.83 IDO1 (0.47) NT5EKDM1ANOTUMRAPGEF4IDO1
SCHEMBL27610724 0.81 IDO1 (0.46) NT5EKDM1ANOTUMRAPGEF4IDO1
SCHEMBL3234438 0.79 ALDH1A1 (0.42) NT5EHSD11B1ALDH1A1PTGDR2LMNA
SCHEMBL4435565 0.77 GRIN2B (0.39) KDM1ARXRAGRIN1GRIN2BPTGDR2
SCHEMBL29465742 0.77 GRIN2B (0.39) KDM1ARXRAGRIN1GRIN2BPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506190-B1 (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER HOFFMANN LA ROCHE (CH) 2006-06-14 EP disclosed
US-7005432-B2 Substituted imidazol-pyridazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-02-28 US disclosed
EP-1506190-A1 (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER F. HOFFMANN-LA ROCHE AG (CH) 2005-02-16 EP disclosed
US-20030229096-A1 Substituted imidazol-pyridazine derivatives EVOTEC INTERNATIONAL GMBH (DE) 2003-12-11 US disclosed
WO-2003097637-A1 (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER F. HOFFMANN-LA ROCHE AG (CH) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229096-A1 Substituted imidazol-pyridazine derivatives GRIN2B, GRIN2A, GRIN2C NT5E 1612/4885HSD11B1 394/4885ALDH1A1 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.